Cernitin™ pollen extracts are the active ingredients in the worldwide registered products Cernilton® and Cernitol®, belonging to Cernelle without any limitation.
In 1969 Cernilton®, a tablet formulation, was registered by the Japanese health authorities to treat chronic prostatitis, chronic pelvic pain syndrome and benign prostate hyperplasia. Cernilton® became a huge success and is today recognised by Japanese doctors as the preferred choice in the treatment of these disorders.
Cernilton® is one of only two pharmaceutical drugs registered worldwide to treat chronic prostatitis and chronic pelvic pain syndrome effectively. The product has been sold in Sweden since 1959 as Cernitol®.
One of the world’s most used medicine for benign prostate diseases
With more than 1,8 billion daily doses in real world use since 1964, Cernilton®/ Cernitol® is one of the preferred medicines worldwide to treat lower urinary tract symptoms (LUTS) caused by benign prostate diseases. There is a therapeutic and scientific interest in Cernilton® and Cernitol®, verified by the large number of non-clinical pharmacodynamic studies, clinical studies and reviews. These results of the scientific studies are coherent. The observed clinical effects are in accordance with the pharmacodynamic profile, and the clinical studies show efficacy and good tolerability.
The vast majority of scientific clinical publications are based on Cernilton®/Cernitol® manufactured by Cernelle. Pollen based products from other companies on the market, are produced differently and therefore the published documentation should be considered as valid for Cernilton®/Cernitol® only.
Thus, Cernilton® and Cernitol® have a well-established use according to Article 10a of Directive 2001/83/EC as amended by Directive 2004/24/EC of the European Parliament and the Council of 31 March 2004 as herbal medicinal products with an excellent level of safety and efficacy.
Cernilton®/Cernitol® are worldwide registered trademarks belonging to AB Cernelle without any limitation.